BRKRP earnings call summary

Prepared Highlights

• Q4 2025 reported revenue $977.2M, flat YoY, including 4.1% currency tailwind, 0.8% M&A contribution, 5.1% organic decline (CEO, CFO). BSI and BEST segments each had 5.1% organic decline (CEO).
• Full-year 2025 reported revenue $3.44B, +2.1% YoY; organic revenue decline 3.7% (BSI -3.5%, BEST -5.4%); M&A added 3.5%; currency tailwind 2.3% (CEO).
• Q4 2025 non-GAAP operating margin 15.7%, down 240bps YoY; full-year 2025 non-GAAP operating margin 12.6%, down 280bps YoY (CEO, CFO).
• Q4 2025 non-GAAP diluted EPS $0.59, down from $0.76 in Q4 2024 (CEO). Full-year 2025 non-GAAP EPS not explicitly stated in prepared remarks.
• Q4 2025 free cash flow $207M, up ~$54M YoY (CEO, CFO). Operating cash flow $230M, highest in company history (CFO).
• BSI book-to-bill in Q4 2025 >1.0x for second consecutive quarter (CEO, CFO). BSI backlog over 7 months of revenue (CEO).
• BioSpin Group 2025 revenue $879M, mid-single-digit organic decline; 2 fewer gigahertz NMR systems (~$25M headwind) (CEO).
• CALID Group 2025 revenue $1.2B, high-single-digit constant currency growth (CEO).
• Bruker Nano 2025 revenue $1.1B, low-single-digit organic decline (CEO).
• BEST 2025 revenue declined mid-single-digit organic (CEO); multiyear superconducting wire orders >$500M; research instruments orders >$40M for extreme infrastructure (CEO).
• Official FY2026 guidance: reported revenue $3.57B–$3.60B, +4%–5%; organic revenue growth 1%–2%; M&A contribution 1.5%; currency tailwind ~1.5% (CFO).
• FY2026 non-GAAP operating margin: expansion of 250–300bps (organic 300–350bps, offset by 50bps currency headwind) (CFO).
• FY2026 non-GAAP EPS: $2.10–$2.15, +15%–17% (8% currency headwind; constant currency +23%–25%) (CFO).
• Q1 2026 outlook: organic revenue down mid-single-digit; operating margin and EPS down meaningfully vs Q1 2025 (CFO).

Mgmt Quotes

• "We are pleased that in the fourth quarter, we delivered revenues ahead of our expectations." (CEO)
• "We start the year with solid BSI segment backlog of over 7 months of revenue and good bookings momentum resulting from 2 consecutive quarters with BSI book-to-bill greater than 1.0." (CEO)
• "We remain very committed to rapid non-GAAP operating profit margin expansion, and we aim for 250 to 300 bps operating profit margin improvement in ’26 despite and including a 50 bps currency headwind." (CEO)
• "We’re pleased that revenue for the quarter came in about $20 million above our guide expectations." (CFO)
• "We delivered over $100 million in improved working capital performance in the fourth quarter of ’25." (CFO)

Prepared Metrics

Q&A Batch (1-5 of 7)

Q1 — Puneet Souda

• Topic: Margin miss in Q4 2025 and cost initiatives for 2026
• Key points:
  • Q4 2025 margin was 100 bps below expectations: 50 bps from unfavorable mix (idiosyncratic, not likely to repeat), 30 bps from late tariffs offset (expected to be offset in 2026), 20 bps from stronger currency headwind (here to stay).
  • Cost initiatives now expected to yield ~$140 million or higher on an annualized basis (previously $120 million), an additional 10%–15% increase.
  • Q1 2026 expected to be softer; margin ramp starts in Q2, with significant step-up in Q3 and Q4; Q4 2025 had ~$25 million cost savings in OpEx.
• Mgmt stance: Bullish on margin recovery, citing cost actions and non-repeating mix issues; cautious on U.S. ACA/GOV orders, which were still weak in Q4, with improvement expected only in second half of 2026.

Q2 — Michael Ryskin

• Topic: Confidence in 2026 margin execution and revenue pacing
• Key points:
  • Confidence in margin expansion driven by $100–$120 million in cost savings already taken, plus additional costs fully effective by midyear; pricing and supply chain improvements have longer lead times (3–4 quarters).
  • Q1 2026 organic revenue expected down mid-single digits; positive growth starting Q2, aided by easier comps (Q2 2025 was weak) and improving order momentum in biopharma, semi, and China.
  • U.S. ACA/GOV may benefit bookings in second half, but revenue impact likely in Q4 2026 or 2027.
• Mgmt stance: Bullish on margin execution due to cost actions; neutral on near-term revenue, with gradual improvement expected but not a full return to long-term growth rates until 2027.

Q3 — Tycho Peterson

• Topic: End-market assumptions for 2026 and margin drivers
• Key points:
  • End-market assumptions: biopharma low single digits organic growth; semi low single digits; clinical (microbiology) stronger; academic/government flat to low single digits down; industrial flat; applied flat.
  • Molecular diagnostics expected very good growth due to ~30% more Genius platform placements in 2025 than planned, driving pull-through in 2026.
  • Operating profit margin expansion in 2026 is about half from gross margin expansion and half from OpEx.
• Mgmt stance: Bullish on diagnostics and biopharma/semi as highlights; neutral on U.S. ACA/GOV, with no significant revenue contribution until Q4 or 2027.

Q4 — Subhalaxmi Nambi

• Topic: Book-to-bill trends and product roadmap for microbiology/diagnostics
• Key points:
  • Book-to-bill in BSI has been above 1.0 for the last two quarters; expects continued gradual improvement in 2026, aided by easier comps in Q2–Q4.
  • Normalized backlog level for BSI is ~5–5.5 months; may use some backlog in 2026 but not modeling full normalization.
  • Microbiology: first rapid AST gram-negative/positive blood culture claim expected FDA approval in 2026 (before midyear); additional claims in clinical trials.
  • Genius platforms: first assay entering U.S. clinical trials in 2026, but no material revenue impact until 2027–2028; syndromic panels rolling out in Europe in late 2026–2027.
• Mgmt stance: Bullish on long-term product pipeline (cumulative effect over time); neutral on 2026 revenue impact from new products, which still require investment.

Q5 — Douglas Schenkel

• Topic: Q1 2026 organic revenue guidance vs. discrete positive items
• Key points:
  • Q1 2025 had strong organic performance (mid-single digits BSI growth) and strong semi orders; timing of existing orders from H1 2025 creates a headwind for Q1 2026.
  • Semi revenue pushed out of Q4 2025 (~$40 million) expected to be recaptured in first half of 2026, but not all in Q1.
  • No specific NMR pushout; 1.2 gigahertz NMR was delivered in Q4 2025.
  • Mid-single-digit decline in Q1 is the right number, with resumption of organic growth in subsequent three quarters.
• Mgmt stance: Neutral on Q1, citing timing headwinds and conservative guidance; bullish on growth resuming in Q2–Q4.

Q&A Batch (6-8 of 8)

Q6 — Jake (for Luke)

• Topic: 中国地区业务表现与展望
• Key points:
  • 中国业务在Q4实现双位数增长，CRO业务复苏，学术支出优于去年同期（部分可能受刺激措施影响，但界限模糊）。
  • 中国生物制药工具业务明确增长，同时亚太其他地区（韩国、台湾、日本）生物制药趋势改善，半导体计量业务受益。
  • 管理层对2026年中国业绩指引不强，预期基础收入大致持平，并非强劲反弹。
• Mgmt stance: 中性偏谨慎 – 对短期中国增长持保守假设，看好亚太生物制药长期趋势但未纳入2026年指引。

Q7 — Daniel Brennan

• Topic: 美国学术/政府客户及半导体业务展望
• Key points:
  • 2025年全年美国学术/政府（ACA/GOV）预订量下降高双位数（部分季度降幅超20%）。
  • 2026年全球ACA/GOV预期收入持平，美国ACA/GOV仍预计有机下滑；半导体业务预计2026年收入增长低个位数（2025年持平）。
  • 多年度资助不确定性仍存在，但管理层认为额外资金总体上有益（即使非直接用于仪器采购）。
• Mgmt stance: 中性 – 美国政府客户持续疲弱，但半导体和全球ACA/GOV指引温和，未预期大幅改善。

Q8 — Brandon Couillard

• Topic: BSI部门增长排序、超高频NMR系统、利息与现金流
• Key points:
  • 2026年三大BSI部门中，BioSpin预计增长最弱（因超高频NMR仅1台确认收入），B Nano、CALID和BEST有机增长相当，均实现增长。
  • 超高频NMR预计2027年恢复至每年2–3台安装（过去为4台/年）。
  • 2026年净利息支出预计约3,500万–4,000万美元；Q4自由现金流2.07亿美元，受库存改善推动。
• Mgmt stance: 中性偏积极 – 现金流表现亮眼，但BioSpin短期疲弱和利率支出需关注；对2027年超高频恢复抱有信心。